(916) 482-5200

Recent Efforts To Find “Pink Viagra” Halted

Published: November 2, 2010

The drugmaker Boehringer Ingelheim has ceased work on filbanserin, their most recent concoction attempting to treat the recently defined hypoactive sexual desire disorder (HSDD).

The experimental drug was aimed at premenopausal women with a persistent and unexplained lack of sex drive, but was judged largely ineffective with “unacceptable risks”. Many test subjects taking the “pink” pill stopped after experiencing depression or fatigue.

The term “pink Viagra” was unfortunate IMO since Viagra-type medications (phosphodiesterase inhibitors or PDEis) do not treat a loss of libido in men. Given the amount of money that Viagra has made for Pfizer the potential earnings that an effective remedy for HSDD is a better explanation of the term.

Apparently the search must go on for such a medication to treat woman.

If one is found it may earn the label “pink Viagra” from its money making ability, if not its action on physiology.